Methods for inhibiting infectious peritonitis
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.
1. A method of inhibiting infectious peritonitis comprising a Bacteroides fragilis infection in a subject comprising:
intraperitoneally administering to said subject a composition comprising active ingredients granulocyte-macrophage colony-stimulating factor (GM-CSF), fosfomycin, and metronidazole, in an amount sufficient to inhibit said infectious peritonitis comprising a Bacteroides fragilis infection, wherein the amount of each active ingredient is GM-CSF 25 micrograms to 100 micrograms, fosfomycin 2 grams to 8 grams, and metronidazole 500 milligrams to 2 grams.
2. The method according to claim 1 , further comprising administering an additional antimicrobial or antibiotic agent active against bacteria of the Bacteroides fragilis group.
3. The method according to claim 2 , wherein the additional antimicrobial or antibiotic agent comprises a carbapenem.
4. The method according to claim 2 , wherein the additional antimicrobial or antibiotic agent comprises imipenem.
5. The method according to claim 2 , wherein the additional antimicrobial or antibiotic agent comprises an antifungal agent.
6. The method according to claim 5 , wherein the additional antifungal agent comprises fluconazole or caspofungin.
7. The method according to claim 1 , further comprising administering a protease inhibitor suitable for in vivo administration into the peritoneal cavity.
8. The method according to claim 7 , wherein the protease inhibitor suitable for in vivo administration into the peritoneal cavity comprises aprotinin or soybean trypsin inhibitor.
9. The method according to claim 1 , wherein the composition has a pH of between 6.5 and 8.
10. The method according to claim 1 , wherein the subject is a mammal.
11. The method according to claim 1 , wherein the subject is a human.
12. The method according to claim 11 , wherein the human is a child younger than 15 years of age.
13. The method according to claim 11 , wherein the human is an adult of 15 years of age or older.
14. The method of claim 1 , wherein the composition is an aqueous solution comprising GM-CSF at a concentration of 100 micrograms per liter, fosfomycin at a concentration of 8 grams per liter, metronidazole at a concentration of 2 grams per liter, and wherein a volume of the aqueous solution administered as a single dose is in the range of 250 milliliters to 1 liter.
15. The method of claim 1 , wherein the amount of each active ingredient is GM-CSF 50 micrograms, fosfomycin 4 grams, and metronidazole 1 gram.
16. The method of claim 15 , wherein the composition is an aqueous solution comprising GM-CSF at a concentration of 100 micrograms per liter, fosfomycin at a concentration of 8 grams per liter, metronidazole at a concentration of 2 grams per liter, and wherein the volume of the aqueous solution administered as a single dose is 500 milliliters.
17. The method of claim 1 , wherein the GM-CSF is in the form of molgramostim.